Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.

Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE.

J Clin Endocrinol Metab. 2012 Oct;97(10):3744-50. doi: 10.1210/jc.2012-1901. Epub 2012 Aug 1.

PMID:
22855334
2.

Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus.

García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M.

J Clin Endocrinol Metab. 2012 Jan;97(1):234-41. doi: 10.1210/jc.2011-2186. Epub 2011 Oct 26.

PMID:
22031520
3.

Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE.

J Clin Endocrinol Metab. 2010 May;95(5):2248-53. doi: 10.1210/jc.2010-0067. Epub 2010 Mar 19.

PMID:
20305005
4.

Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.

Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY.

Bone. 2013 Oct;56(2):355-62. doi: 10.1016/j.bone.2013.06.029. Epub 2013 Jul 9.

PMID:
23845326
5.
6.

Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus.

Yamamoto M, Yamauchi M, Sugimoto T.

J Clin Endocrinol Metab. 2013 Oct;98(10):4030-7. doi: 10.1210/jc.2013-2143. Epub 2013 Jul 26.

PMID:
23894157
7.

Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes.

Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R.

J Clin Endocrinol Metab. 2012 May;97(5):1737-44. doi: 10.1210/jc.2011-2958. Epub 2012 Mar 7.

PMID:
22399511
8.

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.

van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE.

Eur J Endocrinol. 2012 Apr;166(4):711-6. doi: 10.1530/EJE-11-1061. Epub 2012 Jan 20.

9.

Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women.

Urano T, Shiraki M, Ouchi Y, Inoue S.

J Clin Endocrinol Metab. 2012 Aug;97(8):E1473-7. doi: 10.1210/jc.2012-1218. Epub 2012 May 25.

PMID:
22639287
10.

Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.

Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.

Pediatr Diabetes. 2016 Jun;17(4):289-99. doi: 10.1111/pedi.12288. Epub 2015 Jun 10.

PMID:
26094958
11.

Role of sclerostin in the bone loss of postmenopausal chinese women with type 2 diabetes.

Zhou YJ, Li A, Song YL, Zhou H, Li Y, Tang YS.

Chin Med Sci J. 2013 Sep;28(3):135-9.

PMID:
24074614
12.

Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels.

Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R, Muñoz-Torres M.

Diabetes Care. 2013 Jun;36(6):1667-74. doi: 10.2337/dc12-1691. Epub 2013 Jan 3.

13.

The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.

Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE.

Diab Vasc Dis Res. 2014 Jan;11(1):48-52. doi: 10.1177/1479164113510923. Epub 2013 Nov 12.

PMID:
24227537
14.

Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.

Xu XJ, Shen L, Yang YP, Lu FR, Zhu R, Shuai B, Li CG, Wu MX.

Chin Med J (Engl). 2013 Jul;126(13):2480-4.

PMID:
23823821
15.

Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus.

Raška I Jr, Rašková M, Zikán V, Škrha J.

Cent Eur J Public Health. 2017 Mar;25(1):3-10. doi: 10.21101/cejph.a4717.

16.

High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.

Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA.

J Bone Miner Res. 2012 Dec;27(12):2592-602. doi: 10.1002/jbmr.1718.

17.

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.

Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, Peris P.

Bone. 2013 Nov;57(1):272-6. doi: 10.1016/j.bone.2013.08.016. Epub 2013 Aug 24.

PMID:
23981659
18.

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.

Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E.

Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11.

PMID:
22581647
19.

Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.

Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD.

Osteoporos Int. 2013 Feb;24(2):489-94. doi: 10.1007/s00198-012-1978-x. Epub 2012 Apr 14.

PMID:
22525978
20.

Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.

Reppe S, Noer A, Grimholt RM, Halldórsson BV, Medina-Gomez C, Gautvik VT, Olstad OK, Berg JP, Datta H, Estrada K, Hofman A, Uitterlinden AG, Rivadeneira F, Lyle R, Collas P, Gautvik KM.

J Bone Miner Res. 2015 Feb;30(2):249-56. doi: 10.1002/jbmr.2342.

Supplemental Content

Support Center